• Organizations: SightGlass Vision
New DOT lens data finds 75% pediatric myopia management efficacy after 12 months
Pipeline

New DOT lens data finds 75% pediatric myopia management efficacy after 12 months

Latest clinical results support safety and effectiveness of SightGlass Vision’s Diffusion Optics Technology spectacle lenses—including 1-year following discontinued wear.
FDA grants Breakthrough Device Designation to SightGlass Vision's DOT spectacle lenses
Products

FDA grants Breakthrough Device Designation to SightGlass Vision's DOT spectacle lenses

Technology is designed to potentially slow myopia progression in pediatric patients aged 6-13.
Real-world efficacy of DOT lenses evaluated for pediatric myopia
Products

Real-world efficacy of DOT lenses evaluated for pediatric myopia

Findings from an ECP-targeted survey identifies beliefs and behaviors of a positive environment, including major driving factors of the future.
Four-year data continues to support DOT spectacle lenses for myopia
Research

Four-year data continues to support DOT spectacle lenses for myopia

Four-year data continues to support DOT spectacle lenses for myopia
Positive data supports DOT spectacle lenses for pediatric myopia control
Research

Positive data supports DOT spectacle lenses for pediatric myopia control

SightGlass Vision releases 42-month outcomes on CYPRESS study extension.